The FDA has granted Priority Review to a supplemental application for PADCEV plus pembrolizumab in muscle-invasive bladder ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and ...
Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II ...
Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, ...
Illumina and D3b, have announced a new data partnership aimed at accelerating research in pediatric cancer and rare disease, ...
Researchers from MD Anderson identified DHODH as a key metabolic driver of radiotherapy resistance in lung cancer. Radiation ...
A new study led by UCL researchers suggests that making cancer cells more visible to the immune system could broaden the ...
Researchers at MD Anderson identified DPY30 as a key biomarker and epigenetic regulator that enables pancreatic tumors to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results